Biotech | November 23, 2021
AstraZeneca opens Discovery Centre in Cambridge
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
The company is moving towards complex and more differentiated products
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
Vakrangee’s distribution network across rural India will help penetrate underserved markets
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
Subscribe To Our Newsletter & Stay Updated
